CompaniesOtherUpdated Oct 5, 2026
CAD Therapeutics
Private. CAD Therapeutics is developing Clonicaine™, an investigational product candidate for PTSD being studied through a physician-administered sympathetic-block procedure.
- Last round
- Not recorded
- Backed by
- Not recorded
- Launched
- Not recorded
- People
- 1
Overview
Updated Oct 5, 2026
Every fact carries a numbered source. Where we can't source something, it says so.
Identity fields from the company record are sourced where a source is recorded; those have no number.
- Headquarters
- NEW YORK NEW YORK · as of 2026-10-012
- Sector
- Not recorded
- Geography
- NEW YORK NEW YORK
- Founded
- Not recorded
Funding Not recorded
Opportunities For accredited investors
Ways to invest in this company through an Alphaneo vehicle, when one exists. This section looks the same on every company page until you have an accredited profile.
Opportunities, terms and data rooms are shown to accredited investors. Creating a profile takes two minutes, and you’re notified first when anything opens.
No live opportunities right now. Accredited investors are notified first when one opens.
Create an accredited profileA vehicle is never smaller than $1,000,000.
People
Who leads CAD Therapeutics?
Names and titles only, each sourced.
- Christopher J. TeasChief Executive Officer1
Sources
Every claim on this page traces to one of these. The numbers match the citations above.
- 1CAD Therapeutics — A Physiological Approach to PTSD opens in a new tabWebsite, People · accessed Oct 5, 2026
- 2SEC Form D — CAD Therapeutics, Inc. opens in a new tabHeadquarters · accessed Oct 5, 2026